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Abstract
Background: Previous studies have shown that major depressive disorder (MDD) is associated with a variety of cognitive deficits, which can persist even in 
remitted states. Nevertheless, the relationship between the cognitive and affective symptoms in depression remains obscure. The aim of the present study was 
to explore the clinical characteristics and correlates of the cognitive deficits in patients with MDD. Methods: Clinical and neuropsychological assessments 
were conducted at baseline and 6-month follow-ups. The severity of the disease and the effect of treatment were assessed with the Hamilton Depression 
Scale-17. Neuropsychological tests, including the digital symbol substitution test and digit span test, were administered to 67 depressed patients and 56 
healthy participants. Results: MDD patients showed impairments in memory, attention, and executive function at baseline. After the 6-month treatment 
phase, patients in remission showed significant alleviation of these cognitive deficits, although impairments in attention and executive function were still 
present when compared to controls. Discussion: Significant cognitive deficits are present in MDD. The speed of remission of cognitive functions seems to be 
slower than and inconsistent with emotional symptoms, which provides new support for the argument that cognitive deficits are independent factors from 
the emotional symptoms in MDD.
Ji Y et al. / Arch Clin Psychiatry. 2020;47(4):101-5
Keywords: Major depressive disorder, cognitive deficits, executive function, remission.
Introduction
Major depressive disorder (MDD) is a common psychiatric disease 
with a high frequency of recurrence, affecting millions of people 
worldwide. In addition to the well- defined depressive symptoms, 
such as low mood, patients suffering from MDD consistently 
complain about cognitive disturbances, which significantly 
exacerbate the burden of this illness1-3. Among the cognitive 
symptoms, impairments in attention, working memory, processing 
speed, and executive function are often reported.
A considerable number of studies have shown that cognitive 
deficits are promising candidates for the core symptoms of MDD, 
and independent risk factors for poor prognosis4-6. Specifically, some 
studies have found that the progression of cognitive symptoms is 
inconsistent with that of depressive symptoms, that the recovery of 
cognitive deficits is slower than the remission of emotional symptoms, 
and finally, cognitive symptoms have been repeatedly reported in 
participants with subclinical depression as well as participants at 
high risk of developing depression7-9. All of these findings suggest 
that the cognitive symptoms are independent of the emotional 
symptoms in MDD. Therefore, some researchers have proposed that 
cognitive deficits are trait rather than state characteristics, namely 
endophenotypes, in MDD10,11. Wieland-Fiedler et al. observed 
deficits in executive function and sustained attention when residual 
symptoms were controlled for statistically, suggesting that they may 
represent trait markers for MDD12.
Nevertheless, existing studies have generally focused on pre-
treatment cognitive function assessments and have mostly been 
comparative studies with healthy controls. To date, there are few 
prospective studies comparing cognitive function before and after 
treatment. Furthermore, most studies have not restricted the types of 
medication taken by participants, thus making it difficult to control 
for the effect of multi-drug combinations on cognitive function. 
Given the above considerations, our study aimed to explore the 
relationship between cognitive function and depressive symptoms in 
MDD by assessing participant performance on neuropsychological 
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tests before and after treatment with a single antidepressant. In 
addition, we analyzed the relationship between cognitive deficits 
and gender, level of education, severity of depression, age of onset, 
episodes, and illness duration to explore the potential correlate 




A total of 67 drug-naive MDD patients were recruited from the 
outpatient clinic at the Second Xiangya Hospital of Central South 
University. Participants had to meet the following inclusion criteria: 
(1) outpatients; (2) aged 18-65 years old; (3) meeting the International 
Statistical Classification of Diseases and Related Health Problems 10 
criteria for a single or recurrent major depressive episode with no 
history of mania or hypomania (the diagnosis was established by a 
consultant psychiatrist after assessment with the Mini International 
Neuropsychiatric Interview); (4) starting a new antidepressant 
monotherapy (either the first one or an altered one) with a washout 
period of at least four weeks; (5) willing to provide informed consent. 
Patients were excluded if they had any of the following conditions: 
(1) any other primary psychiatric disorder; (2) hyperthyroidism or 
hypothyroidism; (3) receiving electroconvulsive therapy or repeated 
transcranial magnetic stimulation; (4) women who were pregnant, 
less than 6 months post-childbirth, or lactating; (5) experiencing 
severe suicidal tendencies.
Healthy control group
A total of 56 healthy controls were recruited during the same period. 
The inclusion criteria were (1) aged 18-65 years old (male or female); 
(2) having a Hamilton Depression Scale-17 (HAMD-17) score lower 
than 7. The remaining criteria were the same as in the MDD group.
All research protocols were approved by the Xiangya second 





The HAMD-1713 was used to assess the severity of depression. It 
includes five subfactors: relating to retardation, insomnia, cognitive 
dysfunction, anxiety/somatization, and weight loss.
(2) Neuropsychological testing
The digit span test14 measures participants’ attention and short-term 
memory. It consists of recalling digit spans forward and backward. 
The forward test mainly assesses working memory, while the 
backward test assesses attention switching capacity.
The digital symbol substitution test (DSST)14,15 is part of the 
Wechsler Intelligence Scale (digital symbol coding). It measures 
cognitive function, including executive function, visual orienting, 
processing speed, attention, and memory function, which in 
combination represent the ability to conduct complex cognitive 
multitasking.
Assessment methods
The MDD group received one type of selective serotonin reuptake 
inhibitors (SSRIs) from baseline for a period of 6 months. The 
HAMD-17 score was used to assess the severity of depression, 
and neuropsychological tests were employed to measure cognitive 
function in MDD before and after the treatment (i.e., at the 
8- week and 6-month follow-up assessments). The control group 
also completed the above assessments. The clinical assessments and 
cognitive tests were completed by two researchers, with a consensus 
(Kappa) coefficient of 0.90.
Remission was defined as a period of at least 2 months during 
which the individual was diagnosed as being in clinical remission 
with a HAMD-17 score ≤7. After the 6-month period of treatment, 
we successfully conducted follow-up assessments with 44 patients. 
Among these, 17 patients had achieved remission whereas the 
remaining 27 patients did not meet the criterion for remission.
Statistical analysis
SPSS 22.0 statistical software was used to conduct chi-square tests, 
independent sample t tests, paired t tests, covariance analyses, and 
linear regression analyses. The significance level for all analyses was 
set at P < 0.05.
Results
Characteristics of cognitive function in MDD
As shown in Table 1, the total sample was composed of 67 MDD 
patients and 56 healthy controls. Except for the severity of the 
illness, no statistical differences were found between the MDD 
patients and healthy controls in terms of demographic and clinical 
characteristics at baseline. At the 8-week follow-up, data could not 
be obtained from 19 patients. At the 6-month follow-up, data could 
not be obtained from 4 patients. Further analyses were conducted 
on 44 patients, 27 of whom were in clinical remission. As can be 
seen in Table 2, at baseline the depressed patients experienced more 
severe emotional symptoms and demonstrated poorer performance 
on each neuropsychological test compared to the healthy controls. 
At the 8-week follow-up assessment, the emotional symptoms 
and cognitive deficits in the patients showed obvious alleviation 
relative to baseline, although the DSST and backward digit span 
performance were both still significantly poorer than in controls. 
At the 6-month follow-up assessment, the depressed patients still 
had poorer performance on the DSST and backward digit span 
than the controls.
As shown in Table 3, the non-remitted patients demonstrated 
poorer performance on all neuropsychological tests except the 
forward digit span at the 6-month follow-up as compared to healthy 
controls. However, the remitted patients had poorer performance 
only on the DSST, achieving a comparable level of performance to 
that of the healthy controls on the forward and backward digit span 
at the 6-month follow-up.
Clinical correlates of the cognitive deficits in MDD
We used linear regression analysis with cognitive function at baseline 
as the dependent variable and various clinical characteristics of the 
patients (gender, age at onset, level of education, number of episodes, 
illness duration, and severity of depression) as the independent 
variables.
As shown in Table 4, DSST performance was positively 
correlated with level of education and negatively correlated with 
the age of depression onset and illness duration. The forward 
digit span was positively correlated with level of education and 
negatively correlated with the age of depression onset and number 
of episodes. The backward digit span was positively correlated 
with level of education and negatively correlated with HAMD-17 
scores. Linear regression analysis showed that level of education, 
age of depression onset, and illness duration explained 37.0% 
of the variance in DSST performance; level of education, age of 
depression onset, and number of episodes explained 30.6% of the 
variance in forward digit span performance; and level of education 
and HAMD-17 scores explained 14.2% of the variance in backward 
digit span performance.
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Table 4. Linear regression analyses of clinical predictors and cognitive deficits at baseline
Independent variables Dependent variables B β Constant R2 F P









82.233 0.370 9.192 0.001
0.040
0.002









7.670 0.306 8. 259 0.020
<0.001
0.040






3.964 0.142 5.298 0.030
0.049









Digital symbol substitution test (DSST)
Correct 54.06±11.65* 64.85±8.37 65.82±13.60 6.392 0.002
Digit span test
Forward 9.29±0.85 9.74±0.94 9.64±1.17 0.982 0.193
Backward 5.06±0.90* 5.81±0.83* 6.36±1.54 6.926 0.002
Note: *P < 0.05 vs. controls.











HAMD-17 20.91±2.51# 9.73±2.91*# 7.57± 3.37*# 2.46±1.94 523.578 <0.001
Digital symbol substitution test (DSST)
Correct 49.79±10.93# 58.02±9.80*# 60.64±11.05*# 65.82±13.60 20.852 <0.001
Digit Span Test
Forward 8.64±1.08# 9.31±0.75* 9.59±0.92* 9.64±1.17 12.656 <0.001
Backward 4.85±0.97# 5.48±1.01*# 5.48±0.90*# 6.36±1.54 17.665 <0.001
Note: *P < 0.05 vs. baseline. #P < 0.05 vs. controls.
Table 1. Demographic and clinical characteristics for all participants (mean ± SD)
MDD (N=67) Controls (N=56) Statistics (t/χ2) P
Age (years) 31.00 ± 9.84 33.83 ± 12.83 1.385 0.169
Sex (male/female) 30/37 25/31 1.374 0.241
Education (years) 13.18 ± 3.08 13.30 ± 4.70 0.169 0.886
Duration (months) 16.96 ± 15.21 - - -
Age of onset (years) 22.36 ± 5.39 - - -
Number of episodes 3.72 ± 2.17 - - -
First-episode/total 27/67 - - -
HAMD-17 20.91 ± 2.51 2.46 ± 1.94 45.934 0.000
Discussion
The characteristics of cognitive deficits in MDD
The results of the present study indicate that significant cognitive 
deficits are present in MDD, including deficits in executive 
function, attention, and memory. At 6-month follow-up after 
treatment, patients demonstrated significant improvement on all 
three neuropsychological tests, among which the forward digit 
span recovered to the level of healthy control, while the backward 
digit span and digit symbol substitution test performance remained 
suboptimal. These findings suggest that the trajectories of different 
aspects of cognitive function in MDD are asynchronous, and some 
may be independent of emotional symptoms. Specifically, the 
improvement in working memory (as tested by the forward digit span 
task) was the most obvious, as patients exhibited improvement in this 
function even when they did not achieve clinical remission. The speed 
of the improvement in executive function (as tested by the DSST) was 
slower since only patients with clinical remission showed recovery 
from impairment on this task. Meanwhile, the recovery of attention 
switching (as tested by backward digit span) was minimal and had 
little relation to emotional symptoms, since the deficits in attention 
persisted even in the patients who had achieved clinical remission.
Our results are consistent with a considerable number of previous 
literature reviews
and longitudinal studies. For instance, Lee and colleagues found 
that attention and executive functioning deficits were not associated 
with depression severity, suggesting that they may function as 
important trait markers for MDD16. This is consistent with a recent 
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study by Douglas et al. demonstrating that psychomotor speed 
improved in successfully-treated in-patients with severe depression 
whereas attention and executive dysfunction persisted despite 
remission of depressive symptoms17.
However, the findings of some studies are inconsistent with the 
present results. For instance, a recent study found that executive 
dysfunction appeared to be a state-specific marker of MDD that 
is related to depression severity and is not present in remission18,19. 
Maalouf et al. found that the executive dysfunction of adolescent 
patients was correlated with the severity of depression and gradually 
returned to normal level in remission20. One possibility is that the 
adolescent brain may be better able to recover from executive 
function deficits associated with depression. These inconsistencies 
in findings could be partly due to the testing of cognitive dysfunction 
in MDD being limited by heterogeneous demographic features (such 
as age and educational attainment), clinical characteristics (such as 
first, multi-episode, or chronic depression, severity of symptoms, age 
of disease onset, substance use, and comorbid medical conditions), 
and treatment assignments. In our study, some patients were given 
benzodiazepines, while Buffett’s study found that benzodiazepines 
produce profound increases in subjective sedation, slow psychomotor 
and cognitive processing speed, and lead to attentional impairments21. 
Together, these variables likely play a major role in contributing to the 
inconclusive findings reported in the existing studies. In addition, the 
lack of standard tools for assessing cognition in MDD and the variety 
of neuropsychological tests employed in different investigations 
hinder clear comparisons between studies.
The correlates of cognitive deficits in MDD
We found that education level and age of depression onset are major 
factors associated with cognitive deficits in MDD. Similarly, there 
are different degrees of correlation between cognitive deficits and 
episodes, illness duration, and severity of symptoms.
As shown in the present study, working memory, attention 
switching, and executive function are consistently associated with 
level of education, which indicates that more highly educated patients 
show enhanced cognitive reserve capacity Many previous studies are 
consistent with our results. For instance, Jarema et al. showed that 
more highly educated patients demonstrated better performance 
on all the assessed measures of cognitive function22. In addition, 
a study focusing on cognitive functioning in healthy older adults 
found that participants with a medium or high level of education 
performed better on cognitive tests than participants with a low level 
of education. In other words, people with a high level of education 
may have a greater cognitive reserve capacity than people with a 
lower level of education23.
Since the age of depression onset is closely correlated with 
different aspects of cognitive function, late-onset depression may 
be associated with more severe cognitive impairments24,25. A meta-
analysis found that patients with late-onset depression showed greater 
reductions in processing speed and executive function than patients 
with early-onset depression and controls16,26. One explanation for 
this may be that cognitive function, especially executive function, 
may gradually decrease with age. In addition, late-onset depression 
has been associated with cerebrovascular disease risk factors, which 
may also play an important role in the development of cognitive 
impairment27.
However, several limitations must be acknowledged. In this 
study, patients were treated with a single antidepressant, meanwhile 
some also received benzodiazepine in combination, but we did not 
specifically discuss the type and dose of antidepressant used, which 
may impact negatively on cognitive function. We did not discuss 
comorbidities, marital status and family history of mental illness. The 
above factors may affect cognitive function and social function to 
some extent. The neuropsychological assessment tools in this study 
are relatively limited, involving only executive function, attention 
and memory, which cannot comprehensively evaluate the cognitive 
function of patients with depression. Therefore, more comprehensive 
assessment tools should be included in future studies.
In conclusion, patients with MDD may exhibit impairments in 
various cognitive domains, including attention, executive function, 
and memory. While, the trajectories of different aspects of cognitive 
function in MDD are asynchronous during remission, and some 
may be independent of emotional symptoms. Cognition is thus a 
key target in the treatment of depression especially with respect to 
early recognition and intervention. In view of the above findings, 
it is appropriate to conclude that attention deficits and executive 
dysfunction may serve as trait markers of MDD, while working 
memory deficits may be regarded as a state marker of MDD. Whether 
cognitive dysfunction is a state- or trait-related phenomenon in 
depression is a subject of ongoing debate. A promising approach 
to clarifying this matter is the additional consideration of clinical 
and demographic factors that are known to be related to cognitive 
performance. This is an important goal since cognitive deficits 
contribute to long-term functional outcomes, and MDD patients 
experiencing deficits may show less compliance with treatment and 
an increased risk for suicide. 
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